文章摘要

文章信息/Info

Title:: -

作者:: 王东侠; 谭茗月; 中南大学湘雅医学院第二附属医院心内科，湖南长沙 410011

Author(s):: -

关键词:: 促红细胞生成素; 心血管疾病; 细胞凋亡

Keywords:: -

分类号:: R459.1；R54

DOI:: -

文献标识码:: A

摘要:: 促红细胞生成素是一种造血细胞生长因子,主要用于治疗多种原因所致的贫血，最近的研究表明其具有多种非促造血方面的细胞保护作用,包括抗细胞凋亡、促血管生成作用等, 可在心脏缺血损伤、心力衰竭等心血管疾病中发挥心肌细胞、组织的保护作用，从而为心血管疾病的治疗提供广阔前景。

Abstract:: -

参考文献/References

［1］Nishiya D, Omura I，Shimada K,et al.Effects of erythropoietin on cardiac remodeling after myocardial infarction［J］. J Pharmacol Sci，2006, 101(1): 31-39.

［2］Hirata A,Minamino T,Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol3 kinasedependent pathway in canine hearts［ J ］. Cardiovasc Drugs Ther，2005,19(1): 33-40.

［3］Lipsic E , van der Meer P , Henning RH ,et al. Timing of erythropoietin treatment for cardioprotection in ischemia/ reperfusion［J］. J Cardiovasc Pharmacol，2004 ,44(4):473-479.

［4］Tada H , Kagaya Y , Takeda M , et al. Endogenous erythropoietin system in nonhematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion［J］. Cardiovasc Res,2006 ,71(3):466-477.

［5］Fiordaliso F , Chimenti S , Staszewsky L , et al.A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemiareperfusion injury［J］.Proc Natl Acad Sci U S A,2005,102(6):2046-2051.

［6］ Abdelrahman M , Sharples EJ , Mcdonald MC , et al.Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia［J］. Shock,2004,22(1):63-69.

［7］Lipsie E , van der Meer P, Voors AA ,et al.A single bolus of a longacting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study［J］.Cardiovasc Drugs Ther,2006,20(2):135-141.

［8］Miki T , Miura T , Yano T, et al.Alteration in erythropoietininduced cardioprotective signaling by postinfarct ventricular remodeling［J］. J Pharmacol Exp Ther，2006,317(1):68-75.

［9］Bullard AJ, Yellon DM .Chronic erythropoietin treatment limits infarctsize in the myocardium in vitro［J］. Cardiovasc Drugs Ther,2005, 19(5):333-336.

［10］Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure ［J］.Circulation，2004,110(2):149-154.

［11］Hirata A , Minamino T ,Asanuma,et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs ［J］.J Am Coll Cardiol,2006,48(1):176-184.

［12］Li Y , Takemura G , Okada H , et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure［J］. Cardiovasc Res,2006，71(4):684-694.

［13］Mitsuma W , Ito M , Kodama M ,et al. Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis［J］. Biochem Miophys Res Commun,2006,344(3):987-994.

［14］Li LH, Takemura G, Li YW, et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicinInduced cardiomyopathy［J］.Circulation, 2006,113(4):535-543.

我们的网站为什么显示成这样？

促红细胞生成素在心血管疾病中的应用进展(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics